慢性乙型肝炎病毒感染中免疫控制的异质性：干扰素-α治疗

StephenW

慢性乙型肝炎病毒感染中免疫控制的异质性：干扰素-α治疗和再治疗对免疫的临床意义
尹国庆 1 , 陈克平 2 , 顾晓春 2
隶属关系
隶属关系

    1
    东南大学中大医院肝病中心，江苏南京 210009 [email protected]。
    2
    东南大学中大医院肝病中心，江苏南京 210009

    PMID：36353205 PMCID：PMC9639659 DOI：10.3748/wjg.v28.i40.5784

抽象的

乙型肝炎病毒（HBV）感染是一个全球性的公共卫生问题。干扰素-α (IFN-α) 治疗已用于治疗乙型肝炎超过 20 年，但接受 IFN-α 治疗的亚洲人中只有不到 5% 的人实现了功能性治愈。因此，已引入 IFN-α 再治疗以增强抗病毒功能。近年来，免疫相关研究发现，免疫细胞和细胞因子之间复杂的相互作用可以调节免疫反应网络，包括先天免疫和适应性免疫，从而触发控制HBV复制的免疫反应。然而，控制 HBV 感染的免疫系统的异质性，特别是 HBV 特异性 CD8+ T 细胞的异质性，对基于 T 细胞的免疫疗法治疗 HBV 感染具有相应的影响。总之，宿主的遗传变异、负反馈调节因子和 HBV 成分会影响免疫系统控制 HBV 的能力。在本研究中，我们回顾了有关影响 HBV 免疫控制的潜在免疫机制以及 IFN-α 治疗和再治疗的临床效果的文献。

关键词：慢性；功能性治愈；乙型肝炎病毒;异质性；免疫控制；免疫;干扰素-α；再治疗。

©作者 2022。由百视登出版集团有限公司出版。保留所有权利。
利益冲突声明

利益冲突声明：所有作者均未报告与本文相关的利益冲突。

StephenW

Heterogeneity of immune control in chronic hepatitis B virus infection: Clinical implications on immunity with interferon-α treatment and retreatment
Guo-Qing Yin  1 , Ke-Ping Chen  2 , Xiao-Chun Gu  2
Affiliations
Affiliations

    1
    Center of Hepatology, Zhong-Da Hospital, Southeast University, Nanjing 210009, Jiangsu Province, China. [email protected].
    2
    Center of Hepatology, Zhong-Da Hospital, Southeast University, Nanjing 210009, Jiangsu Province, China.

    PMID: 36353205 PMCID: PMC9639659 DOI: 10.3748/wjg.v28.i40.5784

Abstract

Hepatitis B virus (HBV) infection is a global public health issue. Interferon-α (IFN-α) treatment has been used to treat hepatitis B for over 20 years, but fewer than 5% of Asians receiving IFN-α treatment achieve functional cure. Thus, IFN-α retreatment has been introduced to enhance antiviral function. In recent years, immune-related studies have found that the complex interactions between immune cells and cytokines could modulate immune response networks, in-cluding both innate and adaptive immunity, triggering immune responses that control HBV replication. However, heterogeneity of the immune system to control HBV infection, particularly HBV-specific CD8+ T cell heterogeneity, has consequ-ential effects on T cell-based immunotherapy for treating HBV infection. Altogether, the host's genetic variants, negative-feedback regulators and HBV components affecting the immune system's ability to control HBV. In this study, we reviewed the literature on potential immune mechanisms affecting the immune control of HBV and the clinical effects of IFN-α treatment and retreatment.

Keywords: Chronic; Functional cure; Hepatitis B virus; Heterogeneity; Immune control; Immunity; Interferon-α; Retreatment.

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

StephenW

https://doi.org/10.3748/wjg.v28.i40.5784